Prochlorperazine

Phenothiazine — NERVOUS SYSTEM

Key facts

Prochlorperazine is an ofp drug in the Phenothiazine class catalogued in DrugCentral. It was first approved by the FDA in 1956. DrugCentral lists 36 molecular targets, including DRD2, DRD3 and ADRA2B. Recorded indications include Nausea and vomiting, Nonpsychotic Anxiety, Prolonged-Severe Nausea and Vomiting and Schizophrenia.

• Approval status: ofp (first approved 1956 by the FDA).
• Drug class: Phenothiazine.
• Molecular targets: DRD2, DRD3, ADRA2B and ADRA2C (36 listed in DrugCentral).
• Indications: Nausea and vomiting, Nonpsychotic Anxiety, Prolonged-Severe Nausea and Vomiting and Schizophrenia.
• ATC code: N05AB04 (Phenothiazines with piperazine structure).
• Molecular formula: C20H24ClN3S; molecular weight 373.95 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Nausea and vomiting
• Nonpsychotic Anxiety
• Prolonged-Severe Nausea and Vomiting
• Schizophrenia

Off-label uses (2)

• Chemotherapy-induced nausea and vomiting
• Migraine

Contraindications (69)

• Achalasia of esophagus
• Acute disease of cardiovascular system
• Alcoholism
• Anemia
• Angina pectoris
• Angle-closure glaucoma
• At risk for aspiration
• Atony of colon
• Autonomic dysreflexia
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Bleeding
• Bradycardia
• Brain damage
• Breastfeeding (mother)
• Carcinoma of female breast
• Chronic disease of respiratory system
• Chronic heart failure
• Chronic lung disease
• Coma
• Complete trisomy 21 syndrome
• Conduction disorder of the heart
• Congenital long QT syndrome
• Disease of liver
• Disorder of coronary artery
• Disturbance of salivary secretion
• Drowsy
• Drug AND/OR toxin-induced diarrhea
• Epilepsy
• Extrapyramidal disease
• + 39 more

Mechanism & targets

• Established pharmacologic class: Phenothiazine

Molecular targets (36)

Target	Gene	Action	Activity
D(2) dopamine receptor	DRD2	antagonist	Ki 8.76
D(3) dopamine receptor	DRD3	antagonist	Ki 8.61
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 8.32
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 7.92
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 7.89
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 7.82
Histamine H1 receptor	HRH1	unknown	Ki 7.72
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 7.64
Alpha-1A adrenergic receptor	ADRA1A	unknown	Ki 7.62
Alpha-1A adrenergic receptor	Adra1a	unknown	IC50 7.49
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 7.31
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 7.20
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 7.19
D(4) dopamine receptor	DRD4	unknown	Ki 7.17
D(1A) dopamine receptor	DRD1	unknown	Ki 7.11
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 6.91
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 6.91
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 6.80
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 6.72
5-hydroxytryptamine receptor 4	HTR4	unknown	Ki 6.71

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1956-10-23	FDA	—	GLAXOSMITHKLINE

ATC classification

ATC code	Therapeutic hierarchy
N05AB04	NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Phenothiazines with piperazine structure

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Febrile neutropenia	2320.5
Nausea	600.0
Dehydration	546.3
Plasma cell myeloma	527.3
Fatigue	505.1
Drug ineffective	497.2
Diarrhoea	472.5
Death	449.0
White blood cell count decreased	404.6
Disease progression	400.1
Systemic lupus erythematosus	331.6
Vomiting	313.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Prochlorperazine is on its molecule page.

• Molecular formula: C₂₀H₂₄ClN₃S
• Molecular weight: 373.95 g/mol
• CAS number: —
• InChIKey: WIKYUJGCLQQFNW-UHFFFAOYSA-N
• PubChem CID: 4917

CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Prochlorperazine used for?

DrugCentral lists the following indications for Prochlorperazine: Nausea and vomiting, Nonpsychotic Anxiety, Prolonged-Severe Nausea and Vomiting and Schizophrenia.

How does Prochlorperazine work?

Its molecular targets in DrugCentral include DRD2 (antagonist), DRD3 (antagonist), ADRA2B and ADRA2C.

When was Prochlorperazine first approved?

Prochlorperazine was first approved by the FDA in 1956.

What drug class does Prochlorperazine belong to?

Prochlorperazine is in the Phenothiazine class.

What is the chemical formula of Prochlorperazine?

Prochlorperazine has the molecular formula C20H24ClN3S and a molecular weight of 373.95 g/mol.

Sources

• DrugCentral drug card 2274 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201154 — compound record and bioactivity
• PubChem CID 4917 — chemical identifiers
• DrugBank DB00433 — drug record
• FDA UNII YHP6YLT61T — substance identity
• DailyMed: FDA labels for Prochlorperazine — current prescribing information (label search)
• UniProt P14416 (DRD2) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt P18089 (ADRA2B) — target protein
• UniProt P18825 (ADRA2C) — target protein
• UniProt P25100 (ADRA1D) — target protein
• UniProt P28223 (HTR2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.